Novo Nordisk A/S
(NYSE : NVO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.37%145.200.7%$948.12m
PFEPfizer Inc. -0.08%35.730.9%$900.55m
MRKMerck & Co., Inc. -0.66%82.600.7%$692.09m
ABBVAbbVie, Inc. 0.37%86.231.9%$659.16m
BMYBristol-Myers Squibb Co. 1.67%59.221.0%$624.16m
LLYEli Lilly & Co. 0.06%148.901.1%$561.38m
AZNAstraZeneca Plc 0.07%54.211.2%$245.83m
NVSNovartis AG 0.28%86.540.2%$164.20m
GSKGlaxoSmithKline Plc 0.56%37.590.2%$105.60m
PRNBPrincipia Biopharma, Inc. 0.01%99.960.0%$80.21m
NVONovo Nordisk A/S 0.40%68.540.1%$57.25m
SNYSanofi -1.08%50.240.2%$48.80m
RGENRepligen Corp. 0.48%140.617.1%$47.76m
RPRXRoyalty Pharma Plc 1.32%40.760.2%$47.25m
OPKOPKO Health, Inc. 1.14%3.1111.2%$44.20m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.